Suspension of trading

Valuation CureVac

Stocks

Market Closed - Nasdaq 01:00:00 06/01/2026 +04			5-day change	1st Jan Change
4.660 ^USD	-0.21%		-.--%	+3.10%

04-15	Evotec Taps CureVac Executive as COO	MT
01-06	CureVac ends coverage after BioNTech acquisition

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024
Market Cap ¹	11,695	5,643	1,073	852.9	738.8
Change	-	-51.75%	-80.98%	-20.54%	-13.37%
Enterprise Value (EV) ¹	10,425	4,860	619.7	492.2	296
Change	-	-53.38%	-87.25%	-20.57%	-39.86%
P/E	-67.9x	-13.6x	-4.28x	-3.23x	4.57x
PBR	16.8x	8.2x	2.06x	1.65x	1.06x
PEG	0.7x	-0x	0.1x	0.3x	-0x
Capitalization / Revenue	239x	54.8x	15.9x	15.9x	1.38x
EV / Revenue	213x	47.2x	9.19x	9.16x	0.55x
EV / EBITDA	-81.6x	-4.66x	-2.96x	-1.93x	1.33x
EV / EBIT	-78.1x	-4.62x	-2.74x	-1.81x	1.41x
EV / FCF	180x	-6.81x	-1.69x	-3.25x	5.64x
FCF Yield	0.56%	-14.7%	-59.2%	-30.8%	17.7%
Dividend per Share ²	-	-	-	-	-
Rate of return	-	-	-	-	-
EPS ²	-0.9767	-2.213	-1.317	-1.18	0.72
Distribution rate	-	-	-	-	-
Net sales ¹	48.87	103	67.42	53.76	535.2
EBITDA ¹	-127.7	-1,044	-209.6	-254.9	222.6
EBIT ¹	-133.6	-1,053	-226.3	-271.7	209.8
Net income ¹	-129.1	-411.7	-249	-260.2	162.2
Net Debt ¹	-1,270	-782.6	-453.7	-360.6	-442.8
Reference price ²	66.275	30.169	5.642	3.809	3.294
Nbr of stocks (in thousands)	176,460	187,050	190,244	223,924	224,314
Announcement Date	27/04/21	28/04/22	25/04/23	25/04/24	11/04/25